Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis

Background and Aims: In patients with <i>Rat sarcoma proto-oncogene</i> (<i>RAS</i>) wild-type metastatic colorectal cancer (mCRC), anti-epidermal growth factor receptor (EGFR) antibodies have been established in first- and further therapy lines. Due to limited treatment opti...

Full description

Bibliographic Details
Main Authors: Martin S. Schulz, Sebastian Wolf, Vera Struck, Niklas Thomas, Gabriele Husman, Stefan Zeuzem, Christine Koch, Jörg Trojan, Andreas Anton Schnitzbauer, Wolf Otto Bechstein, Oliver Waidmann
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
chemorefractory metastatic colorectal cancer
anti-EGFR therapy
re-exposure
rechallenge
reintroduction
Online Access:https://www.mdpi.com/2072-6694/14/7/1641

Internet

https://www.mdpi.com/2072-6694/14/7/1641

Similar Items